Igf1R Predicts Better Survival in High-Grade Serous Epithelial Ovarian Cancer Patients and Correlates with Hctr1 Levels

References

• Saini SK , SrivastavaS, SinghY, DixitAK, PrasadSN. Epidemiology of epithelial ovarian cancer, a single institution-based study in India. Clin. Cancer Investig. J.5(1), 20 (2016).
   Google Scholar
• Shinagare AB , O’NeillAC, ChengSet al. Advanced high-grade serous ovarian cancer: frequency and timing of thoracic metastases and the implications for chest imaging follow-up. Radiology277(3), 733–740 (2015).
   PubMed Web of Science ®Google Scholar
• Raja F , ChopraN, LedermannJ. Optimal first-line treatment in ovarian cancer. Ann. Oncol.23(Suppl. 10), x118–x127 (2012).
   PubMed Web of Science ®Google Scholar
• Luo Y , LeeM, KimHS, ChungHH, SongYS. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine95(36), e4797 (2016).
   PubMed Web of Science ®Google Scholar
• Hsu K , ShenM, HuangYet al. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br. J. Cancer113(3), 414 (2015).
   PubMed Web of Science ®Google Scholar
• Huang J , HuW, SoodAK. Prognostic biomarkers in ovarian cancer. Cancer Biomark.8(4–5), 231–251 (2011).
   Web of Science ®Google Scholar
• Eckstein N , ServanK, HildebrandtBet al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res.69(7), 2996–3003 (2009).
   PubMed Web of Science ®Google Scholar
• Denduluri SK , IdowuO, WangZet al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis.2(1), 13–25 (2015).
   PubMed Web of Science ®Google Scholar
• Henríquez-Hernández LA , LloretM, PinarBet al. BCL-2, in combination with MVP and IGF-1R expression, improves prediction of clinical outcome in complete response cervical carcinoma patients treated by radiochemotherapy. Gynecol. Oncol.122(3), 585–589 (2011).
   PubMed Web of Science ®Google Scholar
• Zhao S , QiuZ, HeJ, LiL, LiW. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. Int. J. Clin. Exp. Pathol.7(10), 6694 (2014).
   PubMed Web of Science ®Google Scholar
• Åhlén J , WejdeJ, BrosjöOet al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin. Cancer Res.11(1), 206–216 (2005).
   PubMed Web of Science ®Google Scholar
• Heskamp S , BoermanOC, Molkenboer-KuenenJDet al. Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. PLoS ONE10(2), e0117745 (2015).
   PubMed Web of Science ®Google Scholar
• Yerushalmi R , GelmonKA, LeungSet al. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res. Treat.132(1), 131–142 (2012).
   PubMed Web of Science ®Google Scholar
• Gaikwad SM , GunjalL, JunutulaAR, AstaneheA, GambhirSS, RayP. Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models. PLoS ONE8(2), e55971 (2013).
   PubMed Web of Science ®Google Scholar
• Koo CL , KokLF, LeeMYet al. Scoring mechanisms of p16 INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J. Transl. Med.7(1), 25 (2009).
   PubMedGoogle Scholar
• Ahmed AA , EtemadmoghadamD, TempleJet al. Driver mutations in TP53 are ubiquitous in high-grade serous carcinoma of the ovary. J. Pathol.221(1), 49–56 (2010).
   PubMed Web of Science ®Google Scholar
• Singh RK , GaikwadSM, JinagerA, ChaudhuryS, MaheshwariA, RayP. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Cancer Lett.354(2), 254–262 (2014).
   PubMed Web of Science ®Google Scholar
• Bhargava R , BeriwalS, McManusK, DabbsDJ. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma. Appl. Immunohistochem. Mol. Morphol.19(3), 218–225 (2011).
   PubMedGoogle Scholar
• Farabaugh SM , BooneDN, LeeAV. Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front. Endocrinol. (Lausanne)6,59 (2015).
   PubMed Web of Science ®Google Scholar
• Burges A , BrüningA, DannenmannCet al. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch. Gynecol. Obstet.281(3), 511–517 (2010).
   PubMed Web of Science ®Google Scholar
• Sieh W , KöbelM, LongacreTAet al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis Consortium study. Lancet Oncol.14(9), 853–862 (2013).
   PubMed Web of Science ®Google Scholar
• Werner H . Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene31(22), 2703 (2012).
   PubMed Web of Science ®Google Scholar
• Chen SJ , KuoCC, PanHY, TsouTC, YehSC, ChangJY. Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Oncotarget.7(31), 49310 (2016).
   PubMedGoogle Scholar
• Jiang P , WuX, WangX, HuangW, FengQ. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget7(28), 43337 (2016).
   PubMed Web of Science ®Google Scholar